7 results
To obtain an estimate of the anterograde PCI success rate for patients with a confirmed target CTO in each treatment group and to explore safety and tolerability in these patients.
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
To assess the performance of the EndoRotor, as compared to conventional endoscopic techniques, for direct endoscopic necrosectomy (DEN) of walled off necrosis (WON)
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
To investigate if subjects with an increased risk of developing spondyloarthritis have evidence of bone formation on [18F] Fluoride PET-CT.
The aim is to investigate the therapeutic effects of Secukinumab on bone formation in SpA patients by using [18F]Fluoride PET-CT imaging, and to investigate cellular and molecular pathology in bone formation.
The primary objective of this proof-of-concept study is to investigate the feasibility of whole body [18F]Fluoride PET-CT scans to detect axial and peripheral neew bone formation in PsA patients taht are at risk to develop clinically manifest PsA.…